Colonoscopy, endoscopy, fecal calprotectin, CRP, imaging, intestinal ultrasound, and monitoring research.
Page 2 of 4 · 162 articles
IL‑23 inhibitors are an important and growing class of drugs for Crohn’s disease. Comparing them helps patients and clinicians understand differences in trial results, approvals, and possible treatment choices.
Clinical trials are how new IBD tests and treatments are developed; joining one can give access to interventions and helps improve care for people with Crohn’s disease or ulcerative colitis. The article gives practical...
Based on the title and source metadata, this appears to be a guideline related to Tests and monitoring. The original article is from msn.com.
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...
Noninfectious (aseptic) abscesses or persistent lymphadenitis can be an early extraintestinal sign of IBD in children. Recognizing this link can prompt appropriate imaging and endoscopic evaluation that may lead to...
This study suggests using both faecal calprotectin and intestinal ultrasound together can better identify patients who reach deeper, transmural healing — and those patients had lower risk of bowel-damage progression....
Genetic ancestry can influence IBD risk and disease course, and most prior studies focused on European populations.
Fatigue is a common, often persistent symptom in Crohn’s disease even during remission. This study suggests brain structure differences may be linked to fatigue when inflammation is low, pointing to potential...
Based on the title and source metadata, this appears to be a guideline related to Inflammatory bowel disease and Tests and monitoring. The original article is from msn.com.
People with IBD have a higher lifetime risk of colorectal cancer; updated UK guidelines give clinicians and patients evidence-based recommendations on when and how to do surveillance colonoscopy to detect precancerous...
This is a patient-friendly summary explaining what Crohn’s disease is, common symptoms, and typical treatment and monitoring approaches. It can help people recognize symptoms and understand basic management options.
This article gives a clear, patient-friendly overview of Crohn’s disease: what it is, common symptoms and complications, likely causes, and how doctors diagnose it. That context can help people recognize when to seek...
Earlier detection of small-bowel Crohn’s disease with capsule endoscopy could help guide earlier or more targeted treatment and may lower flare rates, which matters to people trying to avoid disease progression and...
Distinguishing Crohn’s from ulcerative colitis can be hard and often requires invasive tests. A reliable blood test would speed diagnosis and help patients start the right treatments sooner. This study is an early step...
The findings suggest B cells and shared antibody responses may play a role in Crohn’s disease, which could point to new biomarkers or targets for future research. For patients, this helps explain why scientists are...
This matters because regular ileocolonoscopies are invasive, costly, and carry risks. If fecal calprotectin reliably rules out significant recurrence for people in deep remission or with low‑risk findings, some patients...
Understanding immune cells that help keep gut inflammation in check could point to new ways to predict flares or develop treatments. If low gamma delta IEL levels are confirmed as an early marker, that might help...
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease and Tests and monitoring. The original article is from cureus.com.
Biologics are a common and important treatment option for people with moderate to severe Crohn’s disease; knowing when they’re used and their potential risks helps patients discuss treatment choices with their care team.
This study suggests LVV can occur in people with IBD at younger ages and with distinct vascular findings, and it may arise even when gut disease is in remission. That matters for awareness, diagnosis, and coordination...
Cobblestone ulcers are a visible sign doctors rely on to tell Crohn’s disease apart from other IBD types, which can speed accurate diagnosis and the start of appropriate testing and treatment. The article also summarizes...
Fatigue is a common, burdensome symptom in Crohn's disease and hard to treat. This study links fatigue severity to differences in brain resting-state connectivity, suggesting brain–gut interactions may play a role.
This study suggests viral exposures—specifically Epstein–Barr virus—might be associated with later development of Crohn’s disease, which could help researchers study disease triggers. If confirmed, such findings might...
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and AI and data science. The original article is from frontiersin.org.
Cure8 found this source from hmpgloballearningnetwork.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Tests and monitoring. Open the original article...
Patients with IBD or new symptoms should understand that Crohn’s disease and ulcerative colitis can look very similar but affect different parts of the gut and may require different treatments. Accurate diagnosis matters...
If approved, TREMFYA (guselkumab) could become an additional IL‑23 inhibitor option for adults with moderate‑to‑severe Crohn’s disease, including both IV and SC induction dosing. That may affect treatment choices for...
You can have active intestinal inflammation even without clear symptoms; early monitoring and tailored treatment aim to prevent complications and preserve quality of life.
Based on the title and source metadata, this appears to be a biomarker study related to Crohn's disease, Ulcerative colitis, and Inflammatory bowel disease. The original article is from msn.com.
Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for...
IBD can present in uncommon ways in children — including as an intraluminal abdominal mass that mimics tumors. Early recognition avoids misdiagnosis and guides appropriate surgical and medical follow-up.
If you have moderate to severe Crohn’s disease, this study suggests some patients who don’t respond to initial risankizumab induction may still benefit from a longer induction period, including improved symptoms and...
Chronic inflammation in Crohn’s, especially when the colon is affected, raises colorectal cancer risk over time. Knowing risk factors and recommended screening helps people with Crohn’s get earlier detection and...
A biomarker that appears before inflammation could help detect Crohn’s disease earlier or predict relapses. Understanding early immune changes may point to new preventive strategies rather than only treating inflammation...
This study provides real‑world data on upadacitinib’s ability to produce clinical and endoscopic remission in people with Crohn’s disease, information that can help patients and clinicians weigh treatment options.
This is a new FDA approval of an IL-23 inhibitor (guselkumab) for adults with moderately to severely active Crohn disease, adding another biologic treatment option. It’s notable because guselkumab offers both IV and...
An FDA approval means guselkumab (Tremfya) is now an authorized treatment option for adults with active Crohn’s disease. The drug offers both subcutaneous and IV induction choices and may be relevant for people who did...
An FDA approval means a new, approved IL‑23 inhibitor option (guselkumab/TREMFYA) is available for adults with moderately to severely active Crohn’s disease, potentially expanding treatment choices and offering a fully...
Unintentional weight loss and malnutrition are common in Crohn’s and can affect energy, healing, and treatment. Practical diet and monitoring steps can help manage weight and nutrition. Working with your healthcare team...
Reducing long-term corticosteroid use matters because steroids have significant side effects when used repeatedly or chronically. The study suggests ileocaecal resection may lower steroid exposure for many patients, but...
This study suggests intestinal ultrasound findings early after diagnosis — especially achieving “transmural remission” within 3 months — may predict better 1-year outcomes (sustained steroid-free remission and less need...
IBS and Crohn’s can look similar, so knowing warning signs helps people get the right tests and treatment sooner. Early evaluation can rule out inflammatory diseases like Crohn’s and identify conditions such as celiac...
Cure8 found this source from precisionmedicineonline.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Biomarker. Open the original article for the full...
Cure8 found this source from hmpgloballearningnetwork.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Tests and monitoring. Open the original article...
Based on the title and source metadata, this appears to be a clinical study related to Irritable bowel syndrome, Upadacitinib, and JAK inhibitor. The original article is from msn.com.
This study reports that upadacitinib produced clinical responses and steroid-free remission in a majority of patients with refractory Crohn's disease at 12 weeks, which may be relevant for people who have not responded...
This study points to a possible microbiome biomarker (M. gnavus) tied to joint inflammation in people with Crohn’s disease, which could help explain why some patients develop arthritis and might eventually inform...
The study identifies a specific gut bacterium, Mediterraneibacter gnavus, that may act as a biomarker for joint inflammation in people with Crohn's disease. Understanding microbiome–immune links could eventually help...
